Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency’s biosimilars policy framework

December 11, 2018 – Our public health obligations touch on many aspects of how medical products are developed and used by patients and providers. The bedrock of our mission is our consumer protection role – our obligation to protect patient safety. Part of our mission also inspires us to promote beneficial innovations that can advance patient care. And along the way, as we pursue these twin goals, we also take steps to inspire competition that can help lower … (leggi tutto)